ReviewBrain and behavior2026
Neurocognitive Aging Following Acute Illness: Pathobiology and a Framework for Developing Neurotherapeutic Agents.
Review in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this paper is to synthesize current mechanistic insights and translational progress on neurocognitive aging after critical illness and to outline a framework for developing neurotherapeutic drugs for clinical application.
methodThe method includes a narrative, focused review of clinical studies in patients' neurocognitive symptoms after critical illness, such as sepsis, trauma, and burns, reported up to December 2025. Evidence was organized across domains, including acute systemic inflammation (ASI), communication channels to the central nervous system (CNS), neuroinflammation and neural integrity, autoimmunity in critically ill patients, and potential therapeutic targets and strategies. FINDING: Acute illness and inflammatory states, including sepsis, trauma, and burns, can lead to accelerated neurocognitive aging, early-onset cognitive impairment, and memory loss. In acute and critical illness, this is attributed to neuroinflammation, microvascular damage, blood-brain barrier (BBB) disruption, and microglial activation resulting from ASI and immune dysregulation. Current research suggests that it also induces cellular senescence, triggering immune dysregulation and subsequent autoimmunity and autoantibody production, contributing to the progression of neurocognitive aging amid chronic low-grade inflammation and inflammaging. These processes affect the function and integrity of the CNS, leading to neurocognitive decline.
conclusionThis review examined the scientific basis for the development of neurocognitive aging after acute illness and how this information may be used to develop potential targets to modulate inflammatory and immune responses and treat this debilitating condition. Such interventions may reduce the burden of senescent cells, mitigate BBB breakdown, restore immune balance, and enhance the brain's neuroplasticity and resilience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.